by mapolzan@aihep.org | Oct 10, 2024 | Uncategorized
By Craig Lammert, M.D. AIHA Executive Director Over the past decade, numerous studies have clearly shown that individuals with autoimmune hepatitis (AIH) experience a lower overall quality of life compared to those without AIH. Adding to these challenges, there...
by Erin Anderson | Jan 30, 2024 | Uncategorized
By Craig Lammert, M.D., AIHA Executive Director Azathioprine (Imuran) has reigned as the most common medication to treat autoimmune hepatitis (AIH) beyond steroids for more than 50 years. Yet, over the years, patients and doctors have raised concerns with its use....
by admin | Jun 30, 2023 | Uncategorized
By Craig Lammert, M.D., AIHA Executive Director Two types of autoimmune hepatitis (AIH) have historically been recognized: Type 1 and Type 2. The type 2 variety, identified as having antibodies anti-LKM1 or LC1, has been identified as more common in children than...
by admin | Jun 12, 2023 | Uncategorized
By the Autoimmune Hepatitis Association Two amazing young adults with AIH have stepped up to form a Young Adult Support Group for patients between the ages of 18 and 40 and their loved ones. This new group will meet monthly on the last Sunday of each month at 8...
by admin | May 17, 2023 | Uncategorized
By Craig Lammert, M.D. AIHA Executive Director The bubonic plague often conjures images of flea bites and grotesque swollen lymph nodes. But when people think of the Black Death, should they also think of autoimmune diseases? As a race, humans have faced a number of...
by admin | May 13, 2023 | Uncategorized
The Autoimmune Hepatitis Association The treatment for autoimmune hepatitis (AIH) hasn’t changed much in the past 60 years; however, a newer steroid called budesonide has been increasingly used since it may have fewer steroid side effects compared to prednisone....
Recent Comments